Latest News and Press Releases

– Ongoing analysis of interim data from the Phase 2 study of ABP-450 in chronic migraine, which did not achieve its primary or secondary endpoints – – Evaluating next-steps across the Company’s...

IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum...

IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum...

IRVINE, Calif., March 30, 2024 (GLOBE NEWSWIRE) -- Regarding a release issued under the same headline on March 29, 2024 by AEON Biopharma, Inc. (NYSE: AEON; AEON.WS), please note that in the first...

IRVINE, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON; AEON.WS) (“AEON” or “the Company”), a clinical-stage biopharmaceutical company focused on developing a...

– Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine – ...

– FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine – – An interim analysis from the ongoing...

-- Termination of the Forward Purchase Agreements simplifies AEON’s capitalization structure -- -- AEON to expand its Board of Directors with appointment of candidate selected by its strategic...

– Open label extension (OLE) Phase 2 data show peak efficacy for all ABP-450 doses and cycles in treating cervical dystonia (CD) occurred early, within 4 weeks; durability of effect was demonstrated...

– Expect to announce topline data in Q3 2024 – – Company plans in Q1 2024 an end-of-phase 2 meeting with the FDA to discuss the Phase 3 program in episodic migraine – – Anticipate shortening the...